Link
- Argentinean Network of Women Living with HIV-AIDS
- Asia Pacific Network of People Living with HIV/AIDS
- bilaterals.org
- Cambodian People Living with HIV/AIDS Network (CPN+)
- Delhi Network of Positive People (DNP+)
- Essentialdrugs.org
- FACEBOOK PAGE: Stop the EU India Free Trade Agreement
- FTA Malaysia
- Health Action International – Asia Pacific
- Intellectual Property Watch
- Lawyers Collective HIV/AIDS Unit
- MSF Access Campaign
- National Association of People Living with HIV and AIDS in Nepal (NAPN)
- Public Citizen
- Stop Peru FTA
- Thai Network of People Living with HIV/Aids (TNP+)
- Third World Network
Take Action
Archives
-
Recent Posts
- The Cost of Price: Why and How to Get Beyond Intellectual Property Internalism
- WHA 65 adopted the resolution for way forward on CEWG report on R&D
- Corporations Win Big in Battle Against Investment Regulation
- US and EU Derailing Ten-year Process to Create Health Research & Development Convention
- MSF: Update on debates at World Health Assembly on a possible R&D convention, 23 May 2012
Categories
Monthly Archives: November 2011
Video: India: Novartis Tries to Weaken Patent Laws That Protect Patients
Posted in Generic drug, Novartis Case, Sec 3 (d), Uncategorized
Leave a comment
Novartis update by Lawyers Collective: Supreme Court to hear Novartis’ petition in February–March 2012 [29 November 2011]
29 November 2011, New Delhi. Novartis’ Special Leave Petition (SLP) before the Supreme Court of India challenging the decision of the Intellectual Property Appellate Board (IPAB) rejecting its appeal for a patent on the beta-crystalline form of imatinib mesylate, an … Continue reading
Posted in Novartis Case, patent evergreening, Sec 3 (d)
Tagged Gleevac, India Supreme Court, Novartis
Leave a comment
Stop the India-EU FTA Negotiations, Decimator of the ‘Pharmacy of the World’! Dismiss the Novartis’ case! Abolish the KORUS FTA right now!
US and EU are threatening lives of people living with disease now. The India-EU FTA is an agreement which risk patients’ health none the more than the KORUS FTA. Especially, the India-EU FTA endangers lives of people living with disease … Continue reading
Posted in EU-India FTA, Korea-US FTA, Novartis Case
Leave a comment
Novartis case: New date and the government’s defence
Loon Gangte (DNP+): Today, looking at the sensitivity of the Novartis Case and the time required to hear the matter properly, the Court has decided to give it more time and has scheduled it for the 28th of February 2012. These will be … Continue reading
Posted in Novartis Case, patent evergreening, Sec 3 (d)
Leave a comment
Press Release: Chaotic US – Korean Free Trade Agreement can seriously affect public health response in South Korea
Bangkok, Thailand, 27 November 2011: We, the under signed civil society organisations working on HIV, AIDS and human rights express grave concern about the manner in which the KORUS Free Trade agreement was passed in the South Korean Parliament on … Continue reading
Posted in Korea-US FTA, TRIPS plus
Leave a comment
Leaked Text: Draft Chapter of IP of India-EFTA FTA
Click here to see the draft text of Intellectual Property Rights chapter being negotiated between India and EFTA as in 2009. EFTA-India FTA – IPR Chapter, 2009 Delegations from the four EFTA States and India met for a ninth round … Continue reading
Posted in India-EFTA FTA
Leave a comment
INDIA UNDER PRESSURE TO GIVE UP ON GENERIC PRODUCTION – FTA NEGOTIATIONS AND NOVARTIS CASE
Health and HIV groups should be concerned about the future of low cost generic production as both – FTA negotiations on intellectual property (IP) with the European Commission (EC) and the Novartis legal challenge to a key public health safeguard in the Indian patent … Continue reading
Posted in data exclusivity, EU-India FTA, Generic drug, India-EFTA FTA, Novartis Case, Sec 3 (d)
Tagged Imatinib, Supreme court
1 Comment
Bayer withdraws writ petition against Natco’s CL application
24-11-11 Source: Livemint C.H. Unnikrishnan Bayer had in the writ petition challenged the Indian patent office’s decision to publish Natco’s compulsory licensing application for public review Mumbai: In a new twist to the ongoing legal battle between German drug multinational … Continue reading
Posted in Compulsory Licensing
Tagged Bayer, Delhi High Court, Indian Patent Office, Natco, Sorafenib
Leave a comment
South Korea Clears U.S. Trade Deal
Wall Street Journal Nov 23, 2011 By EVAN RAMSTAD South Korean legislators scuffled and one opposition MP let off a teargas device, briefly clearing the chamber. South Korea’s ruling conservatives pushed a controversial free trade deal with the United States … Continue reading
Posted in Korea-US FTA
Leave a comment
Lancet article by Joseph E Stiglitz: Trade agreements and health in developing countries
Source: Lancet 31-Jan-2009 Politicians champion free trade for bringing an era of high and stable growth, although the evidence supporting such claims is ambiguous. Studies that associate increases in trade with increases in gross domestic product often leave open questions of … Continue reading
Posted in data exclusivity, Generic drug, IP Rights, TRIPS plus
Leave a comment
